elder law weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of elder law weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Optimer Pharmaceuticals, Inc.
Medical advisory board assembled to guide development of CDAD treatment
June 23rd, 2004
Optimer Pharmaceuticals, Inc., has recently assembled a group of medical experts to guide the development of its lead drug candidate, OPT-80, for the treatment of Clostridium difficile-associated diarrhea (CDAD). When patients are treated with broad-spectrum antibiotics, C. difficile can grow in the bowel, produce toxins, and cause severe diarrhea. CDAD is the primary cause of nosocomial diarrhea worldwide. The mortality rate can be as high as 20% among elderly and debilitated patients. OPT-80 is being developed to address the major unmet medical need to combat CDAD. "OPT-80's key advantage over current antibiotic drugs is its potent...
Source: elder law weekly (2004-06-23)
|
